Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The development of CNS-active LRRK2 inhibitors using property-directed optimisation
Formula: C50H88N14O15
TGX221 is a selective inhibitor for ccRCC with both VHL and SETD2 mutations
PubMed PMID: 14327696
CAS Number: 64622-45-3
Faropenem Catalog No.:M16831-C The development of CNS-active LRRK2Faropenem is a potent and orally active beta lactam antibiotic. Faropenem demonstrates broad spectrum in vitro antimicrobial activity against many gram positive and negative aerobes and anaerobes. Faropenem is resistant to hydrolysis by nearly all beta lactamases, including extended spectrum beta lactamases and AmpC beta lactamases. Faropenem is developed as an oral prodrug, faropenem medoxomil, for the research of respiratory tract infections.